Pfizer Stock Slips After Beat-And-Raise Quarter

You’ll need to open a brokerage account to buy and sell stocks. Most brokerage companies require you to be at least 18 years of age to open an account. https://www.1investing.in/ You’ll need to provide some identifying information, such as your name, date of birth, Social Security number, and contact information.

Investing in Pfizer stock FAQ

1. However, the valuation multiple has fluctuated in a wide range in recent years due to a strong earnings growth during the Covid-19 pandemic phase, driven by its vaccine and antiviral therapy.
2. This led to the advancement of fermentation technology that was later used in the commercial production of penicillin and then the advancement of antibiotics in general.
3. As of the first quarter, it has more than $11.9 billion in cash, cash equivalents, and short-term investments on hand.
4. The company expanded during the late 1800s and early 1900s, remaining a privately held company until June 1942, when it offered shares of its common stock to the public for the first time.
5. If the bigger business makes a bid to buy it, you’ll benefit that way too.
6. We are holding steady to our $42 fair value estimate for Pfizer following slightly better-than-expected second-quarter results.

You’ll need to enter Pfizer’s stock ticker (PFE) and the number of shares you want to buy. You’ll have the option of placing a market order or a limit order. A market order tells your broker to execute the trade immediately. With a limit order, you’re telling your broker to make the purchase only if the stock price dips below a certain level. We are holding steady to our $42 fair value estimate for Pfizer following slightly better-than-expected second-quarter results.

What drugs make Pfizer the most money?

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. Aggressive cost-cutting in research and development could hurt Pfizer’s long-term prospects, given the importance of continued investment in innovation. Pfizer’s pipeline productivity is improving with several successful recent drug launches.

Financial Strength

China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state. But until that day comes, don’t buy this stock with the expectation that an announcement is right around the corner.

358 employees have rated Pfizer Chief Executive Officer Albert Bourla on Glassdoor.com. Albert Bourla has an approval rating of 92% among purpose of internal audit the company’s employees. This puts Albert Bourla in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

In its 2024 guidance, management estimates revenue of $58.5 billion to $61.5 billion, which is relatively flat growth, and earnings per share of $2.05 to $2.25. Once you fund your account, you’ll need to set an investing budget. You’ll need to decide how much to invest in Pfizer and how much to invest overall.

In comparison, returns for the S&P 500 have been 27% in 2021, -19% in 2022, and 24% in 2023 — indicating that PFE underperformed the S&P in 2023. “Pfizer once again delivered better-than-expected results at both the top and bottom line, wrote Lee Brown, global sector lead for healthcare at Third Bridge, in an emailed statement. Pfizer reported a notable year-over-year decline in Q2 earnings, but the results still beat expectations.

Overall, Pfizer has a good history of paying a quarterly dividend and increasing it over time. Though it hasn’t reached Dividend King status just yet, it’s increased its dividend for the past 15 consecutive years. As of Aug. 9, 2021, Pfizer had 5,606,688,356 shares of voting common stock outstanding. Yes, Pfizer pays a regular quarterly cash dividend of $0.39 per share. The FDA gave the vaccine full approval on Aug. 23, 2021, after reviewing the biologics license application (BLA) submitted by Pfizer and BioNTech. The two companies completed their submission of the BLA in May 2021.

This is up from its previous forecast of revenue in the range of $58.5 billion to $61.5 billion and earnings per share in the range of $2.15 to $2.35. In the three months ended June 30, Pfizer said its revenue increased 2.1% year-over-year to $13.3 billion, thanks in part to 22% revenue growth in the U.S. to $7.9 billion. Its earnings per share (EPS) declined 10.4% from the year-ago period to 60 cents. Yet, as mentioned, it’s too soon to give up all hope for Pfizer, especially given its recent acquisitions and promising drugs in its pipeline. For instance, the company is strongly committed to maintaining its dividend and gained myriad new drugs through acquisitions.

Pfizer Inc. (PFE) is a leading global biopharmaceutical company based in New York. The company makes money by developing and manufacturing drug treatments to promote health and prevent disease. Its single operating segment spans a range of therapeutic areas, including oncology, internal medicine, hospital, vaccines, inflammation and immunology, and rare diseases. In FY 2022, Pfizer generated $31.37 billion in net income out of $100.33 billion in annual revenue. The company’s market capitalization was $227 billion as of market close on March 24, 2023.

Likewise, recognize that sometimes clinical trials fail, even in the late-stage programs that are the juiciest targets for purchasing. There’s a risk that an acquisition could end with little to show for the expenditure. Pfizer now anticipates revenue in the range of $59.5 billion to $62.5 billion and EPS in the range of $2.45 to $2.65 in 2024.